E-LIB Suche - Ergebnisse für: Quach, H

1

Response adaptive salvage treatment with daratumumab–lenali..:

Lim, S. ; Reynolds, J. ; Quach, H....
British Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

2

Response adaptive salvage with KTd and ASCT for functional ..:

Turner, R. ; Quach, H. ; Horvath, N....
British Journal of Haematology. 202 (2023) 3 - p. 530-538 , 2023

Link: https://doi.org/10.1111/..

3

OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC..:

Ramos, C. A. ; Quach, D. H. ; Lulla, P. D....
Hematological Oncology. 41 (2023) S2 - p. 83-85 , 2023

Link: https://doi.org/10.1002/..

4

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC..:

Searle, E. ; Quach, H. ; Wong, S....
HemaSphere. 7 (2023) S2 - p. 27-27 , 2023

Link: https://doi.org/10.1097/..

5

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) ..:

Weisel, K. ; Kumar, S. ; Moreau, P....
HemaSphere. 7 (2023) S2 - p. 14-15 , 2023

Link: https://doi.org/10.1097/..

6

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY ..:

Quach, H. ; Parmar, G. ; Ocio, E. M....
HemaSphere. 6 (2022) - p. 835-836 , 2022

Link: https://doi.org/10.1097/..

7

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION A..:

Lesokhin, A. M. ; Arnulf, B. ; Niesvizky, R....
HemaSphere. 6 (2022) - p. 839-840 , 2022

Link: https://doi.org/10.1097/..

8

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS ..:

Usmani, S. Z. ; Mielnik, M. ; Koh, Y....
HemaSphere. 6 (2022) - p. 832-833 , 2022

Link: https://doi.org/10.1097/..

9

P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SUR..:

Chai, K. L. ; Wellard, C. ; Aoki, N....
HemaSphere. 6 (2022) - p. 1454-1455 , 2022

Link: https://doi.org/10.1097/..

10

PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING TH..:

Delimpasi, S. ; Quach, H. ; Cavo, M....
HemaSphere. 6 (2022) - p. 1906-1907 , 2022

Link: https://doi.org/10.1097/..

11

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS ..:

Quach, H. ; Leleu, X. ; Mateos, M.-V....
HemaSphere. 6 (2022) - p. 798-799 , 2022

Link: https://doi.org/10.1097/..

12

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ..:

Quach, H. ; Gironella, M. ; Lee, C....
HemaSphere. 6 (2022) - p. 831-832 , 2022

Link: https://doi.org/10.1097/..

13

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN..:

Lesokhin, AM ; Arnulf, B ; Niesvizky, R...
Hematology, Transfusion and Cell Therapy. 44 (2022) - p. S245-S246 , 2022

Link: https://doi.org/10.1016/..

14

P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN..:

Lasica, M. ; Spencer, A. ; Campbell, P....
HemaSphere. 6 (2022) - p. 836-837 , 2022

Link: https://doi.org/10.1097/..

15

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS S..:

Usmani, S ; Alonso, A ; Quach, H...
HemaSphere. 6 (2022) - p. 19-19 , 2022

Link: https://doi.org/10.1097/..